{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:12:08Z","timestamp":1790061128538,"version":"4.0.1"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"\n Importance<\/jats:title>\n Venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism, is a frequent condition that can lead to significant morbidity and mortality; statins, monoclonal antibody proprotein convertase subtilisin\u2013kexin type 9 (PCSK9) inhibitors, and their combination are associated with a reduced risk of VTE. The effect of bempedoic acid on VTE risk is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether bempedoic acid is associated with a reduced risk of VTE.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n CLEAR Outcomes was a randomized, double-blind, placebo-controlled, cardiovascular outcomes clinical trial. Statin-intolerant individuals at high risk for or with established atherosclerotic cardiovascular disease who were aged 18 to 85 years were enrolled between December 22, 2016, and August 14, 2019, in 1250 centers across 32 countries. The statistical analysis for the present study was conducted between March 10, 2025, and February 19, 2026.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized to oral bempedoic acid, 180 mg, or placebo daily.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome for this analysis was the time to first occurrence of VTE (composite of deep vein thrombosis or pulmonary embolism). The occurrences of deep vein thrombosis and pulmonary embolism were also assessed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 13\u202f970 participants (mean [SD] age, 65.5 [9.0] years; 6740 [48.2%] female) were randomized, 6992 to bempedoic acid and 6978 to placebo. At the time of randomization, 275 participants (2.0%) had a history of VTE, and 1219 (8.7%) were receiving systemic anticoagulation. The participants were followed up for a median (IQR) of 40.6 (37.1-46.2) months. A total of 106 VTE events occurred (39 in the bempedoic acid group and 67 in the placebo group; hazard ratio [HR], 0.58; 95% CI, 0.39-0.86;\n P<\/jats:italic>\n \u2009=\u2009.006). Findings were consistent for deep vein thrombosis (HR, 0.56; 95% CI, 0.31-0.996;\n P<\/jats:italic>\n \u2009=\u2009.045) and pulmonary embolism (HR, 0.61; 95% CI, 0.37-0.996;\n P<\/jats:italic>\n \u2009=\u2009.046).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Treatment with bempedoic acid among participants with statin intolerance at high risk for or with established cardiovascular disease was associated with a reduced risk of VTE.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02993406<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.1208","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:30:29Z","timestamp":1779895829000},"page":"659","source":"Crossref","is-referenced-by-count":5,"title":["Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients"],"prefix":"10.1001","volume":"11","author":[{"given":"Bernardo F.","family":"Spiazzi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Brennan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina P.","family":"Zingano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Powell","sequence":"additional","affiliation":[{"name":"Esperion Therapeutics Inc, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio"},{"name":"Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke J.","family":"Laffin","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio"},{"name":"Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"hbr260012r1","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","article-title":"Thrombosis: a major contributor to global disease burden.","volume":"34","author":"Raskob","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"hbr260012r2","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"issue":"18","key":"hbr260012r3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism.","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"hbr260012r4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/cvr\/cvab078","article-title":"Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials.","volume":"118","author":"Joseph","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"20","key":"hbr260012r5","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial.","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"20","key":"hbr260012r6","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibition on the risk of venous thromboembolism.","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"hbr260012r7","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","article-title":"Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis.","volume":"4","author":"Kunutsor","year":"2017","journal-title":"Lancet Haematol"},{"issue":"35","key":"hbr260012r8","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1093\/eurheartj\/ehae361","article-title":"Lipid lowering for prevention of venous thromboembolism: a network meta-analysis.","volume":"45","author":"Farmakis","year":"2024","journal-title":"Eur Heart J"},{"key":"hbr260012r9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-Outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am Heart J"},{"issue":"15","key":"hbr260012r10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"hbr260012r11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/blood-2004-11-4230","article-title":"LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo.","volume":"106","author":"Bovenschen","year":"2005","journal-title":"Blood"},{"issue":"16","key":"hbr260012r12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease.","volume":"381","author":"Michos","year":"2019","journal-title":"N Engl J Med"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2849617\/jamacardiology_spiazzi_2026_br_260012_1782314640.08816.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:00:41Z","timestamp":1783522841000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2849617"}},"subtitle":["A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.1208","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}